Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Review article: Externally derived control arms-An opportunity for clinical trials in inflammatory bowel disease?

  • Authors : Honap S; Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, UK.; School of Immunology and Microbial Sciences, King's College London, London, UK.

Subjects: Clinical Trials as Topic* ; Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/drug therapy; Humans

  • Source: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Oct; Vol. 58 (7), pp. 659-667. Date of Electronic Publication: 2023 Aug 21.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Representation of Real-World Adults With Chronic Kidney Disease in Clinical Trials Supporting Blood Pressure Treatment Targets.

  • Authors : Li J; Department of Epidemiology and Population Health Stanford University School of Medicine Stanford CA USA.; Geriatric Research and Education Clinical Center VA Palo Alto Health Care Systems Palo Alto CA USA.

Subjects: Hypertension*/Hypertension*/Hypertension*/diagnosis ; Hypertension*/Hypertension*/Hypertension*/drug therapy ; Hypertension*/Hypertension*/Hypertension*/epidemiology

  • Source: Journal of the American Heart Association [J Am Heart Assoc] 2024 Apr 02; Vol. 13 (7), pp. e031742. Date of Electronic Publication: 2024 Mar 27.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited

Record details

×
Editorial & Opinion

Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.

  • Authors : Sharma A; McGill University Health Centre, Montreal, Quebec, Canada.; Marques P

Subjects: Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/epidemiology ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/prevention & control ; Cardiovascular System*

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Feb; Vol. 26 (2), pp. 758-762. Date of Electronic Publication: 2023 Oct 26.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited

Record details

×
Academic Journal

Core Outcome Set for IgE-mediated food allergy clinical trials and observational studies of interventions: International Delphi consensus study 'COMFA'.

Subjects: Food Hypersensitivity*/Food Hypersensitivity*/Food Hypersensitivity*/diagnosis ; Food Hypersensitivity*/Food Hypersensitivity*/Food Hypersensitivity*/therapy ; Quality of Life*

  • Source: Allergy [Allergy] 2024 Apr; Vol. 79 (4), pp. 977-989. Date of Electronic Publication: 2024 Mar 03.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children.

Subjects: Asthma*/Asthma*/Asthma*/drug therapy ; Rhinitis, Allergic*/Rhinitis, Allergic*/Rhinitis, Allergic*/drug therapy ; Rhinitis, Allergic, Seasonal*/Rhinitis, Allergic, Seasonal*/Rhinitis, Allergic, Seasonal*/prevention & control

  • Source: Allergy [Allergy] 2024 Apr; Vol. 79 (4), pp. 1018-1027. Date of Electronic Publication: 2023 Dec 26.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Do medications increase the efficacy of digital interventions for smoking cessation? Secondary results from the iCanQuit randomized trial.

  • Authors : Bricker JB; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Psychology, University of Washington, Seattle, WA, USA.

Subjects: Mobile Applications* ; Smoking Cessation*/Smoking Cessation*/Smoking Cessation*/methods; Female

  • Source: Addiction (Abingdon, England) [Addiction] 2024 Apr; Vol. 119 (4), pp. 664-676. Date of Electronic Publication: 2023 Nov 27.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9304118 Publication Model: Print-Electronic Cited Medium:

Record details

×
Editorial & Opinion

A novel calcipotriol and betamethasone dipropionate (CAL/BDP) PAD-cream demonstrates greater improvements in daily activities and personal relationships than CAL/BDP gel/TS: A post-hoc analysis of DLQI outcomes from two phase 3 placebo-controlled randomized clinical trials in mild-to-moderate psoriasis.

Subjects: Betamethasone*/Betamethasone*/Betamethasone*/therapeutic use ; Betamethasone*/Betamethasone*/Betamethasone*/analogs & derivatives ; Calcitriol*/Calcitriol*/Calcitriol*/analogs & derivatives

  • Source: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Apr; Vol. 38 (4), pp. e326-e328. Date of Electronic Publication: 2023 NovPublisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.

  • Authors : Bhatt AS; Division of Research Kaiser Permanente San Francisco Medical Center San Francisco CA USA.; Division of Cardiovascular Medicine Stanford University School of Medicine Palo Alto CA USA.

Subjects: Glucosides* ; Heart Failure*/Heart Failure*/Heart Failure*/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use

  • Source: Journal of the American Heart Association [J Am Heart Assoc] 2024 Mar 05; Vol. 13 (5), pp. e032279. Date of Electronic Publication: 2024 Feb 23.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited

Record details

×
Academic Journal

Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.

  • Authors : Senna M; Lahey Hospital and Medical Center, Harvard Medical School, Boston, Massachusetts, USA.; Mostaghimi A

Subjects: Alopecia Areata*/Alopecia Areata*/Alopecia Areata*/drug therapy ; Azetidines*/Azetidines*/Azetidines*/adverse effects ; Janus Kinase Inhibitors*/Janus Kinase Inhibitors*/Janus Kinase Inhibitors*/adverse effects Diffuse alopecia

  • Source: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Mar; Vol. 38 (3), pp. 583-593.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print Cited Medium:

Record details

×
Editorial & Opinion

Quick consults in hematology: In support of active surveillance versus treatment of high-risk smoldering multiple myeloma outside of a clinical trial.

  • Authors : Gertz MA; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Subjects: Smoldering Multiple Myeloma*/Smoldering Multiple Myeloma*/Smoldering Multiple Myeloma*/therapy ; Watchful Waiting*; Humans

  • Source: American journal of hematology [Am J Hematol] 2024 Mar; Vol. 99 (3), pp. 465-467. Date of Electronic Publication: 2023 Dec 19.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited

Record details

×
  • 1-10 of  58,611 results for ""CLINICAL trials""